Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
Sanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerSanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated Share XSanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerhttps://pharmaphorum.com/news/sanofis-immunotherapy-libtayo-gets-fda-not-in-first-line-lung-cancer/
Regeneron pairs with BioNTech on melanoma immunotherapyRegeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech Share XRegeneron pairs with BioNTech on melanoma immunotherapyhttps://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/
Regeneron gets closer to ISA Pharma with new immuno-oncology allianceRegeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch Share XRegeneron gets closer to ISA Pharma with new immuno-oncology alliancehttps://pharmaphorum.com/news/regeneron-gets-closer-to-isa-pharma-with-new-immuno-oncology-alliance/
